By Fineline Cube 
China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced plans to acquire 100% stake in Changsha Zhongya Medical Imaging Diagnosis Co., Ltd for RMB 29.5 million (USD 4.1 million). The acquisition aims to integrate Rimag’s standardized products into Zhongya Med’s portfolio and leverage combined resources for synergistic growth in business and regional markets.
Strategic Rationale
The acquisition will allow Rimag Group to combine its product line with Zhongya Medical Imaging’s offerings. This strategic move is designed to create operational efficiencies and expand market reach through the shared resources and capabilities of both companies.-Fineline Info & Tech